Search

Your search keyword '"Papadimitrakopoulou, Vali A"' showing total 116 results
Start Over Author "Papadimitrakopoulou, Vali A"
116 results on '"Papadimitrakopoulou, Vali A"'

1. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

Author

Lin, Steven H., Lin, Yan, Yao, Luyang, Kalhor, Neda, Carter, Brett W., Altan, Mehmet, Blumenschein, George, Byers, Lauren A., Fossella, Frank, Gibbons, Don L., Kurie, Jonathan M., Lu, Charles, Simon, George, Skoulidis, Ferdinandos, Chang, Joe Y., Jeter, Melenda D., Liao, Zhongxing, Gomez, Daniel R., O’Reilly, Michael, Papadimitrakopoulou, Vali, Thall, Peter, Heymach, John V., and Tsao, Anne S.

Published
2020
Full Text
View/download PDF

4. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

Author

Kelloff, Gary J, Lippman, Scott M, Dannenberg, Andrew J, Sigman, Caroline C, Pearce, Homer L, Reid, Brian J, Szabo, Eva, Jordan, V Craig, Spitz, Margaret R, Mills, Gordon B, Papadimitrakopoulou, Vali A, Lotan, Reuben, Aggarwal, Bharat B, Bresalier, Robert S, Kim, Jeri, Arun, Banu, Lu, Karen H, Thomas, Melanie E, Rhodes, Helen E, Brewer, Molly A, Follen, Michele, Shin, Dong M, Parnes, Howard L, Siegfried, Jill M, Evans, Alison A, Blot, William J, Chow, Wong-Ho, Blount, Patricia L, Maley, Carlo C, Wang, Kenneth K, Lam, Stephen, Lee, J Jack, Dubinett, Steven M, Engstrom, Paul F, Meyskens, Frank L, O'Shaughnessy, Joyce, Hawk, Ernest T, Levin, Bernard, Nelson, William G, Hong, Waun Ki, and Prevention, for the AACR Task Force on Cancer

Subjects
Clinical Research, Cancer, Prevention, Clinical Trials and Supportive Activities, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Biomarkers, Tumor, Breast Neoplasms, Chemoprevention, Colorectal Neoplasms, Disease Progression, Female, Humans, Infections, Inflammation, Male, Monitoring, Physiologic, Neoplasms, Glandular and Epithelial, Signal Transduction, AACR Task Force on Cancer Prevention, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.

Published
2006

5. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

Author

Lissanu Deribe, Yonathan, Sun, Yuting, Terranova, Christopher, Khan, Fatima, Martinez-Ledesma, Juan, Gay, Jason, Gao, Guang, Mullinax, Robert A., Khor, Tin, Feng, Ningping, Lin, Yu-Hsi, Wu, Chia-Chin, Reyes, Claudia, Peng, Qian, Robinson, Frederick, Inoue, Akira, Kochat, Veena, Liu, Chang-Gong, Asara, John M., Moran, Cesar, Muller, Florian, Wang, Jing, Fang, Bingliang, Papadimitrakopoulou, Vali, Wistuba, Ignacio I., Rai, Kunal, Marszalek, Joseph, and Futreal, P. Andrew

Published
2018
Full Text
View/download PDF

6. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

Author

O'Shaughnessy, Joyce A, Kelloff, Gary J, Gordon, Gary B, Dannenberg, Andrew J, Hong, Waun Ki, Fabian, Carol J, Sigman, Caroline C, Bertagnolli, Monica M, Stratton, Steven P, Lam, Stephen, Nelson, William G, Meyskens, Frank L, Alberts, David S, Follen, Michele, Rustgi, Anil K, Papadimitrakopoulou, Vali, Scardino, Peter T, Gazdar, Adi F, Wattenberg, Lee W, Sporn, Michael B, Sakr, Wael A, Lippman, Scott M, and Von Hoff, Daniel D

Subjects
Humans, Neoplasms, Carcinoma in Situ, Cervical Intraepithelial Neoplasia, Prostatic Intraepithelial Neoplasia, Colorectal Neoplasms, Mouth Neoplasms, Barrett Esophagus, Cardiovascular Diseases, Keratosis, Antineoplastic Agents, Time Factors, Female, Male, Urinary Bladder Neoplasms, Clinical Trials as Topic, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

Precancer or intraepithelial neoplasia (IEN) is a noninvasive lesion that has genetic abnormalities, loss of cellular control functions, and some phenotypic characteristics of invasive cancer and that predicts for a substantial likelihood of developing invasive cancer. The AACR Task Force on the Treatment and Prevention of IEN has delineated the relationship between IEN and cancer risk as well as the clinical benefit that can be derived from reducing IEN burden. Although several effective endoscopic and surgical treatments for IEN have become standard medical practice, these interventions can confer morbidity and do not treat the entire epithelial field at risk. The incidence of many epithelial cancers is continuing to rise, the number of individuals at risk is increasing with the aging population, and the rapid advancement of imaging and molecular diagnostics is bringing to light precancers that were heretofore clinically silent. There is therefore an urgent need to rapidly develop new treatment and prevention agents for IEN. The AACR IEN Task Force recommends focusing on established precancers as the target for new agent development because of the close association between dysplasia and invasive cancer and because a convincing reduction in IEN burden provides patient benefit by reducing cancer risk and/or by decreasing the need for invasive interventions. The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer.

Published
2002

8. Supplementary Table S1 from Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro

Author

Sano, Daisuke, primary, Matsumoto, Fumihiko, primary, Valdecanas, David R., primary, Zhao, Mei, primary, Molkentine, David P., primary, Takahashi, Yoko, primary, Hanna, Ehab Y., primary, Papadimitrakopoulou, Vali, primary, Heymach, John, primary, Milas, Luka, primary, and Myers, Jeffrey N., primary

Published
2023
Full Text
View/download PDF

10. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

Author

Hah, Hun J., Zhao, Mei, Pickering, Curtis R., Frederick, Mitchell J., Andrews, Genevieve A., Jasser, Samar A., Fooshee, David R., Milas, Zvonimir L., Galer, Chad, Sano, Daisuke, William, William N., Jr, Kim, Edward, Heymach, John, Byers, Lauren A., Papadimitrakopoulou, Vali, and Myers, Jeffrey N.

Published
2014
Full Text
View/download PDF

12. JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

Author

Brahmer, Julie R., primary, Johnson, Melissa L., additional, Cobo, Manuel, additional, Viteri, Santiago, additional, Sarto, Juan Coves, additional, Sukari, Ammar, additional, Awad, Mark M., additional, Salgia, Ravi, additional, Papadimitrakopoulou, Vali A., additional, Rajan, Arun, additional, Bandyopadhyay, Nibedita, additional, Allred, Alicia J., additional, Wade, Mark, additional, Mason, Gary E., additional, Zudaire, Enrique, additional, Knoblauch, Roland E., additional, Stone, Nicole, additional, Lorenzi, Matthew V., additional, and Hassan, Raffit, additional

Published
2021
Full Text
View/download PDF

24. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy

Author

Mao, Li, El-Naggar, Adel K., Papadimitrakopoulou, Vali, Shin, Dong M., Shin, Hyung C., Fan, Youhong, Zhou, Xiao, Clayman, Gary, Lee, J. Jack, Lee, Jin Soo, Hittelman, Walter N., Lippman, Scott M., and Hong, Waun Ki

Subjects
Precancerous conditions -- Drug therapy, Cancer -- Prevention, Skin lesions -- Physiological aspects, Health
Abstract

Background: The goal of chemoprevention is to reduce the risk of cancer development by reversing or blocking the tumorigenic process through the use of pharmacologic or natural agents. To determine the potential role of genetic alterations in assessing cancer risk and in evaluating the efficacy of chemopreventive agents, we studied 22 patients with advanced premalignant lesions of the head and neck who were part of a prospective cancer prevention trial that is investigating a regimen of 13-cis-retinoic acid, interferon alfa, and [Alpha]-tocopherol administered for 12 months or until disease progression. Methods: We used polymerase chain reaction analysis of microsatellite DNA sequences in cells from precancerous lesions to determine the frequencies of genetic alterations--namely, loss of heterozygosity (LOH) and microsatellite instability--at chromosomal loci that are commonly deleted in head and neck cancer. Results: Prior to treatment, 17 (81%) of 21, eight (44%) of 18, and eight (42%) of 19 patients who were informative (i.e., heterozygous) at chromosomes 9p21, 3p14, and 17p13, respectively, exhibited LOH in at least one of their lesion biopsy specimens. Among nine patients who exhibited LOH at chromosome 9p21 in pretreatment biopsy specimens and who had completed at least 5 months of therapy, the genetic loss persisted in eight--including three of the four patients who exhibited complete histologic responses (i.e., no evidence of dysplasia in their biopsy specimens). Implication: Our data suggest that clinical and histologic assessments of the response to chemopreventive agents may be insufficient to determine their efficacy and that critical genetic alterations could be used as independent biomarkers to augment the ability to evaluate the efficacy of such agents. [J Natl Cancer Inst 1998;90:1545-51]

Published
1998

25. Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer

Author

Wang, Yudong, primary, Wang, Zhijie, additional, Piha-Paul, Sarina, additional, Janku, Filip, additional, Subbiah, Vivek, additional, Shi, Naiyi, additional, Hess, Kenneth, additional, Broaddus, Russell, additional, Shan, Baoen, additional, Naing, Aung, additional, Hong, David, additional, Tsimberidou, Apostolia M., additional, Karp, Daniel, additional, Lu, Charles, additional, Papadimitrakopoulou, Vali, additional, Heymach, John, additional, Meric-Bernstam, Funda, additional, and Fu, Siqing, additional

Published
2018
Full Text
View/download PDF

26. Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

Author

Deribe, Yonathan Lissanu, primary, Sun, Yuting, additional, Terranova, Christopher, additional, Khan, Fatima, additional, Martinez-Ledesma, Juan, additional, Gay, Jason, additional, Gao, Guang, additional, Mullinax, Robert A., additional, Khor, Tin, additional, Feng, Ningping, additional, Lin, Yu-Hsi, additional, Wu, Chia-Chin, additional, Reyes, Claudia, additional, Peng, Qian, additional, Robinson, Frederick, additional, Inoue, Akira, additional, Kochat, Veena, additional, Liu, Chang-Gong, additional, Asara, John M., additional, Moran, Cesar, additional, Muller, Florian, additional, Wang, Jing, additional, Fang, Bingliang, additional, Papadimitrakopoulou, Vali, additional, Wistuba, Ignacio I., additional, Rai, Kunal, additional, Marszalek, Joseph, additional, and Futreal, P. Andrew, additional

Published
2018
Full Text
View/download PDF

27. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology

Author

Gridelli, Cesare, primary, Ascierto, Paolo A., additional, Barberis, Massimo C.P., additional, Felip, Enriqueta, additional, Garon, Edward B, additional, O’brien, Mary, additional, Senan, Suresh, additional, Casaluce, Francesca, additional, Sgambato, Assunta, additional, Papadimitrakopoulou, Vali, additional, and De Marinis, Filippo, additional

Published
2016
Full Text
View/download PDF

28. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma

Author

Goepfert, Ryan P., primary, Lewin, Jan S., additional, Barrow, Martha P., additional, Fuller, C. David, additional, Lai, Stephen Y., additional, Song, Juhee, additional, Hobbs, Brian P., additional, Gunn, G. Brandon, additional, Beadle, Beth M., additional, Rosenthal, David I., additional, Garden, Adam S., additional, Kies, Merrill S., additional, Papadimitrakopoulou, Vali A., additional, Schwartz, David L., additional, and Hutcheson, Katherine A., additional

Published
2016
Full Text
View/download PDF

29. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.

Author

Goepfert, Ryan P., Lewin, Jan S., Barrow, Martha P., Fuller, C. David, Lai, Stephen Y., Song, Juhee, Hobbs, Brian P., Gunn, G. Brandon, Beadle, Beth M., Rosenthal, David I., Garden, Adam S., Kies, Merrill S., Papadimitrakopoulou, Vali A., Schwartz, David L., and Hutcheson, Katherine A.

Abstract

Objectives/hypothesis: To determine the factors associated with longitudinal patient-reported dysphagia as measured by the MD Anderson Dysphagia Inventory (MDADI) in locoregionally advanced oropharyngeal carcinoma (OPC) survivors treated with split-field intensity modulated radiotherapy (IMRT).Study Design: Retrospective patient analysis.Methods: A retrospective analysis combined data from three single-institution clinical trials for stage III/IV head and neck carcinoma. According to trial protocols, patients had prospectively collected MDADI at baseline, 6, 12, and 24 months after treatment. OPC patients with baseline and at least one post-treatment MDADI were included. Longitudinal analysis was completed with multivariate linear mixed effects modeling.Results: There were 116 patients who met inclusion criteria. Mean baseline MDADI composite was 88.3, dropping to 73.8 at 6 months, and rising to 78.6 and 83.3 by 12 and 24 months, respectively (compared to baseline, all P < .0001). Tumor stage and smoking status were significant predictors of longitudinal MDADI composite scores. Patients with T1, T2, and T3 tumors had 15.9 (P = .0001), 10.9 (P = .0049), and 7.5 (P = .0615), respectively, higher mean MDADI composite than those with T4 tumors, and current smokers had a 9.4 (P = .0007) lower mean MDADI composite than never smokers.Conclusions: Patients report clinically meaningful dysphagia early after split-field IMRT for locoregionally advanced OPC that remains apparent 6 months after treatment. MDADI scores recover slowly thereafter, but remain depressed at 24 months compared to baseline. Higher tumor stage and smoking status are important markers of patient-reported function through the course of treatment, suggesting these are important groups for heightened surveillance and more intensive interventions to optimize swallowing outcomes.Level Of Evidence: 4 Laryngoscope, 127:842-848, 2017. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

30. First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

Author

Sessa, Cristiana, primary, Shapiro, Geoffrey I., additional, Bhalla, Kapil N., additional, Britten, Carolyn, additional, Jacks, Karen S., additional, Mita, Monica, additional, Papadimitrakopoulou, Vali, additional, Pluard, Tim, additional, Samuel, Thomas A., additional, Akimov, Mikhail, additional, Quadt, Cornelia, additional, Fernandez-Ibarra, Cristina, additional, Lu, Hong, additional, Bailey, Stuart, additional, Chica, Sandra, additional, and Banerji, Udai, additional

Published
2013
Full Text
View/download PDF

31. Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck

Author

Hutcheson, Katherine A., primary, Lewin, Jan S., additional, Holsinger, F. Christopher, additional, Steinhaus, Ganene, additional, Lisec, Asher, additional, Barringer, Denise A., additional, Lin, Heather Y., additional, Villalobos, Sandra, additional, Garden, Adam S., additional, Papadimitrakopoulou, Vali, additional, and Kies, Merrill S., additional

Published
2013
Full Text
View/download PDF

33. Abstract 5605: LKB1 and KRAS mutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancer

Author

Byers, Lauren Averett, primary, Diao, Lixia, additional, Wang, Jing, additional, Girard, Luc, additional, Peyton, Michael, additional, Gazdar, Adi, additional, Groth, Philip, additional, Paul, Julianne, additional, Liu, Ningshu, additional, Kim, Edward S., additional, Mauro, David, additional, Herbst, Roy S., additional, Papadimitrakopoulou, Vali, additional, Coombes, Kevin R., additional, Weinstein, John N., additional, Minna, John D., additional, and Heymach, John V., additional

Published
2012
Full Text
View/download PDF

34. Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro

Author

Sano, Daisuke, primary, Matsumoto, Fumihiko, additional, Valdecanas, David R., additional, Zhao, Mei, additional, Molkentine, David P., additional, Takahashi, Yoko, additional, Hanna, Ehab Y., additional, Papadimitrakopoulou, Vali, additional, Heymach, John, additional, Milas, Luka, additional, and Myers, Jeffrey N., additional

Published
2011
Full Text
View/download PDF

35. Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer

Author

Byers, Lauren Averett, primary, Holsinger, F. Christopher, additional, Kies, Merrill S., additional, William, William N., additional, El-Naggar, Adel K., additional, Lee, J. Jack, additional, Hu, Jianhua, additional, Lopez, Adriana, additional, Tran, Hai T., additional, Yan, Shaoyu, additional, Du, Zhiqiang, additional, Ang, K. Kian, additional, Glisson, Bonnie S., additional, Raso, Maria Gabriela, additional, Wistuba, Ignacio I., additional, Myers, Jeffrey N., additional, Hong, Waun-Ki, additional, Papadimitrakopoulou, Vali, additional, Lippman, Scott M., additional, and Heymach, John V., additional

Published
2010
Full Text
View/download PDF

36. Abstract 369: Treatment with vandetanib can overcome resistance of head and neck squamous cell carcinoma cells to cisplatin and radiation in an orthotopic animal model

Author

Sano, Daisuke, primary, Matsumoto, Fumihiko, additional, Valdecanas, David R., additional, Zhao, Mei, additional, Molkentine, David P., additional, Papadimitrakopoulou, Vali, additional, Heymach, John V., additional, Raju, Uma, additional, Milas, Luka, additional, and Myers, Jeffrey N., additional

Published
2010
Full Text
View/download PDF

37. Abstract 794: Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodology

Author

Yan, Wusheng, primary, Shih, Joanna H., additional, Raso, M. Gabriela, additional, Rodriguez-Canales, Jaime, additional, Behrens, Carmen, additional, Papadimitrakopoulou, Vali A., additional, Herbst, Roy S., additional, Emmert-Buck, Michael R., additional, Wistuba, Ignacio I., additional, and Erickson, Heidi S., additional

Published
2010
Full Text
View/download PDF

38. ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia

Author

Saintigny, Pierre, primary, El-Naggar, Adel K., additional, Papadimitrakopoulou, Vali, additional, Ren, Hening, additional, Fan, You-Hong, additional, Feng, Lei, additional, Lee, J. Jack, additional, Kim, Edward S., additional, Hong, Waun Ki, additional, Lippman, Scott M., additional, and Mao, Li, additional

Published
2009
Full Text
View/download PDF

41. Workshop on imaging science development for cancer prevention and preemption

Author

Kelloff, Gary J., primary, Sullivan, Daniel C., additional, Baker, Houston, additional, Clarke, Lawrence P., additional, Nordstrom, Robert, additional, Tatum, James L., additional, Dorfman, Gary S., additional, Jacobs, Paula, additional, Berg, Christine D., additional, Pomper, Martin G., additional, Birrer, Michael J., additional, Tempero, Margaret, additional, Higley, Howard R., additional, Petty, Brenda Gumbs, additional, Sigman, Caroline C., additional, Maley, Carlo, additional, Sharma, Prateek, additional, Wax, Adam, additional, Ginsberg, Gregory G., additional, Dannenberg, Andrew J., additional, Hawk, Ernest T., additional, Messing, Edward M., additional, Grossman, H. Barton, additional, Harisinghani, Mukesh, additional, Bigio, Irving J., additional, Griebel, Donna, additional, Henson, Donald E., additional, Fabian, Carol J., additional, Ferrara, Katherine, additional, Fantini, Sergio, additional, Schnall, Mitchell D., additional, Zujewski, Jo Anne, additional, Hayes, Wendy, additional, Klein, Eric A., additional, DeMarzo, Angelo, additional, Ocak, Iclal, additional, Ketterling, Jeffrey A., additional, Tempany, Clare, additional, Shtern, Faina, additional, Parnes, Howard L., additional, Gomez, Jorge, additional, Srivastava, Sudhir, additional, Szabo, Eva, additional, Lam, Stephen, additional, Seibel, Eric J., additional, Massion, Pierre, additional, McLennan, Geoffrey, additional, Cleary, Kevin, additional, Suh, Robert, additional, Burt, Randall W., additional, Pfeiffer, Ruth M., additional, Hoffman, John M., additional, Roy, Hemant K., additional, Wang, Thomas, additional, Limburg, Paul J., additional, El-Deiry, Wafik S., additional, Papadimitrakopoulou, Vali, additional, Hittelman, Walter N., additional, MacAulay, Calum, additional, Veltri, Robert W., additional, Solomon, Diane, additional, Jeronimo, Jose, additional, Richards-Kortum, Rebecca, additional, Johnson, Karen A., additional, Viner, Jaye L., additional, Stratton, Steven P., additional, Rajadhyaksha, Milind, additional, and Dhawan, Atam, additional

Published
2006
Full Text
View/download PDF

44. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Author

Khuri, Fadlo R., primary, Glisson, Bonnie S., additional, Kim, Edward S., additional, Statkevich, Paul, additional, Thall, Peter F., additional, Meyers, Michael L., additional, Herbst, Roy S., additional, Munden, Reginald F., additional, Tendler, Craig, additional, Zhu, Yali, additional, Bangert, Sandra, additional, Thompson, Elizabeth, additional, Lu, Charles, additional, Wang, Xue-Mei, additional, Shin, Dong M., additional, Kies, Merrill S., additional, Papadimitrakopoulou, Vali, additional, Fossella, Frank V., additional, Kirschmeier, Paul, additional, Bishop, W. Robert, additional, and Hong, Waun Ki, additional

Published
2004
Full Text
View/download PDF

45. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses c-Src and Pak1 Pathways and Invasiveness of Human Cancer Cells

Author

Yang, Zhibo, primary, Bagheri-Yarmand, Rozita, additional, Wang, Rui-An, additional, Adam, Liana, additional, Papadimitrakopoulou, Vali Vassiliki, additional, Clayman, Gary L., additional, El-Naggar, Adel, additional, Lotan, Reuben, additional, Barnes, Christopher J., additional, Hong, Waun Ki, additional, and Kumar, Rakesh, additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results